1. Home
  2. TBHC vs GRDX Comparison

TBHC vs GRDX Comparison

Compare TBHC & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TBHC

The Brand House Collective Inc.

HOLD

Current Price

$0.92

Market Cap

21.9M

ML Signal

HOLD

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

N/A

Current Price

$4.78

Market Cap

24.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TBHC
GRDX
Founded
1966
N/A
Country
United States
United Kingdom
Employees
4010
2
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.9M
24.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TBHC
GRDX
Price
$0.92
$4.78
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
45.7K
124.4K
Earning Date
04-30-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.86
$1.87
52 Week High
$2.40
$5.30

Technical Indicators

Market Signals
Indicator
TBHC
GRDX
Relative Strength Index (RSI) 42.69 81.25
Support Level N/A $2.08
Resistance Level $1.27 $5.30
Average True Range (ATR) 0.05 0.51
MACD 0.00 0.16
Stochastic Oscillator 47.00 95.14

Price Performance

Historical Comparison
TBHC
GRDX

About TBHC The Brand House Collective Inc.

The Brand House Collective Inc is a specialty retailer of home decor and gifts in the United States. The company stores provide various merchandise, including holiday decor, value pricing, and a stimulating in-store and online environment that provides customers with a brand experience. The company stores also offer an assortment of holiday merchandise in seasonal periods, as well as items that are suitable for gift-giving.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: